Secondary complement-mediated thrombotic microangiopathy successfully treated with eculizumab in patient with cryoglobulinemic vasculitis

Read full text Summarise with VIRAT
Authors: Yulia V. Korotchaeva, N.L. Kozlovskaya, O. Vorobyeva, E. Uvarova, Kseniya A. Demyanova, E. Kolobov, S. Moiseev
Cited by: 0
References: 34

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Thrombotic microangiopathy (TMA) is a syndrome characterized by endothelial injury and thrombotic occlusion of the microvasculature of kidneys and other organs. Clinical manifestations of TMA include microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. Dysregulated complement system activation plays a key role in the pathogenesis of TMA that can be primary (due to the pathogenic variants of the complement genes) or secondary. The latter can be induced by various causes, including drugs, autoimmune diseases, infections, transplantation of hemopoetic cells and solid organs, etc. We report a case of complementmediated TMA successfully treated with eculizumab in patient with HCV-associated cryoglobulinemic vasculitis.

Fields of Study & Subjects

Complement system in diseases Vasculitis and related conditions Renal Diseases and Glomerulopathies

Publication details

Journal / source
Clinical pharmacology and therapy
Volume
35
Issue
1
Pages
65–73
Publication date
13 February 2026
Language
EN